Vol. I / Section 01 / Research
The BPC-157 Research Record
Thirty-three years of preclinical work, indexed by mechanism, tissue, and outcome — followed by what little exists in humans.
Mechanism: what the molecule is reported to do
Across the preclinical record, BPC-157 is described as multi-pathway. The most cited mechanism is angiogenesis through the VEGFR2-PI3K-Akt-eNOS axis: the peptide promotes the formation of new vessels from existing vasculature, an effect documented in muscle and tendon healing with increased VEGF expression and increased CD34/FVIII-positive microvascular density at the injury site[4]. In vitro angiogenic assays on isolated cells are negative, suggesting the effect is contextual and dependent on the wound microenvironment.
A parallel mechanism is nitric oxide modulation. The peptide alters activity across all three nitric oxide synthase isoforms — endothelial (eNOS), neuronal (nNOS), and inducible (iNOS) — and effects often persist under L-NAME inhibition or L-arginine substrate challenge, a finding interpreted as a modulatory rather than substrate-dependent role[7]. Hsieh et al. (2020) reported activation of the Src-Caveolin-1-eNOS pathway in rat aortic preparations, implicating BPC-157 in vasomotor tone regulation[20].
In cultured tendon fibroblasts, Chang et al. (2014) reported a dose- and time-dependent increase in growth hormone receptor mRNA and protein up to sevenfold, with co-incubation with growth hormone amplifying proliferation via JAK2 activation[2]. The peptide is also reported to shift macrophage polarization toward the M2 anti-inflammatory phenotype, modulate ERK1/2 MAPK signaling, and engage the FAK-paxillin pathway relevant to fibroblast migration and collagen organization.
Musculoskeletal models
Tendon. Staresinic et al. (2003) administered 10 μg/kg or 10 ng/kg intraperitoneal to Sprague-Dawley rats following Achilles transection and observed increased load-to-failure, superior collagen and reticulin organization, and macroscopic and microscopic restoration of tendon integrity[1]. Krivic et al. (2006) extended the finding to tendon-to-bone detachment and reported that the peptide counteracted the negative effect of concomitant methylprednisolone — a corticosteroid known to impair tendon healing[3].
Bone. Sebecic et al. (1999) studied a rabbit segmental bone-defect model and reported that BPC-157 at 10 μg/kg, applied locally and intramuscularly, produced bony union comparable to autologous cortical bone grafting or bone-marrow application[5]. The comparison to autograft — the standard against which orthopaedic bone-graft substitutes are measured — is notable; the model has not, to our reading, been replicated by an independent lab.
Muscle. A 2025 study in Pharmaceutics (Matek et al.) reported that per-oral BPC-157 in drinking water at 10 μg/kg/day or 10 ng/kg/day (0.16 μg/mL or 0.16 ng/mL) closed a surgically detached quadriceps-to-bone gap by day 21–28, restored walking pattern, reduced motor function index scores, and produced well-organized periosteum and oriented type-I collagen[14].
Systematic review. Vasireddi et al. (2025) in HSS Journal identified thirty-six BPC-157 articles between 1993 and 2024: thirty-five preclinical, one clinical. The preclinical signal across tendon, ligament, muscle, and bone was characterized as broad; human evidence was characterized as minimal[16].
Gastrointestinal models
BPC-157 was originally framed by its discoverers as a stable gastric pentadecapeptide with cytoprotective action across the gastrointestinal tract. Sikiric et al. (2012) reviewed the colitis literature: cysteamine and vascular-occlusion-related rat colitis models showed reduced colonic ulceration, edema, and inflammatory infiltrate with BPC-157 at 10 μg/kg or 10 ng/kg[24].
A 2024 review in Pharmaceuticals (Bajramagic et al.) catalogued rat intestinal anastomosis studies across four segments — esophagogastric, colocolonic, jejunoileal, and ileoileal — reporting reduced leakage, increased burst pressure, less necrosis, increased epithelialization, more granulation tissue, and fewer inflammatory infiltrates with BPC-157 administration[13].
Fistula models are a recurring endpoint. Klicek et al. (2008) reported closure of colocutaneous fistulas with maintained efficacy under NOS modulation[7]. Vukusic et al. (2024) reported closure of duodenocolic fistulas with reduced adhesion and altered NOS2/COX-2/VEGFA expression[19]. Madzarac et al., published online in early 2026, reported tracheocutaneous fistula closure with normalization of nitric oxide and malondialdehyde levels in a triple NO-agent paradigm — BPC-157 either reversed L-NAME aggravation or enhanced L-arginine-mediated outcomes[23].
The single human trial that exists in this domain is the Pliva Phase II enema program for mild-to-moderate ulcerative colitis (PL 14736). The trial is reported as completed and as well tolerated; full efficacy data were never published in a peer-reviewed clinical paper, and the program was not advanced further[6].
Other organ systems
Peripheral nerve. Gjurasin et al. (2010) studied transected sciatic nerve in rats and reported faster axonal regeneration, greater myelin sheath thickness, increased blood-vessel density at the repair site, and improved sciatic functional index scores under BPC-157 at 10 μg/kg or 10 ng/kg, administered locally and systemically[8].
Spinal cord. Perovic et al. (2019) compressed rat sacrocaudal spinal cord and administered a single intraperitoneal injection at 10 minutes post-injury (200 μg/kg or 2 μg/kg) — note the dose elevation in CNS work — reporting clinical improvement, restored tail motor function, abolished autotomy, and resolved spasticity by day 15, with histology showing reduced vacuolization, less axonal loss, and motoneuron preservation[9].
Brain. Vukojevic et al. (2022) reported in a mouse closed traumatic brain injury model that BPC-157 at 10 μg/kg or 10 ng/kg reduced subarachnoid and intraventricular hemorrhage, brain lacerations, cerebral edema, and post-injury mortality across 24 hours[10].
Distant-organ damage. Demirtas et al. (2025) studied 45 minutes of infrarenal aortic clamping followed by 120 minutes of reperfusion in Wistar rats and reported that 20 μg/kg intraperitoneal BPC-157 reduced histologic damage to liver, kidney, and lung, raised total antioxidant status, lowered total oxidative status, and enhanced paraoxonase-1 activity[12].
The three human reports
McGuire et al. (2025), in Current Reviews in Musculoskeletal Medicine, summarized the entire published human evidence base as three reports from a single investigator group. Lee and Padgett (2021) administered intra-articular BPC-157 to the knees of 16 patients, of whom 14 (87.5%) reported pain relief. Lee et al. (2024) administered 10 mg intravesicular BPC-157 to 12 women with interstitial cystitis previously unresponsive to pentosan polysulfate and reported 80–100% symptom resolution. Lee and Burgess (2025) administered single-arm intravenous infusion up to 20 mg in healthy volunteers and reported tolerability with clearance within 24 hours and no adverse events[17].
The authors of the review note the obvious: all three are small, uncontrolled, and from one group. There is no published randomized controlled trial. There is no actively recruiting registered trial in the major international registries as of this writing — the only Phase I registration on ClinicalTrials.gov, NCT02637284 (PCO-02 in healthy volunteers, 2015), was cancelled in 2016 without published results.
The full published human evidence base consists of three small, uncontrolled pilot reports from one investigator group, between 2021 and 2025. No controlled trial, no Phase III, no FDA approval.
Interpretation
A reader of the BPC-157 literature is asked to reconcile two facts. The first: the preclinical signal is broad, internally consistent across more than thirty years and many tissue types, with biomechanical, histologic, and molecular endpoints converging on a coherent picture of accelerated repair. The second: this signal lives almost entirely in one lab’s rats, has not been independently replicated at scale, and crosses into humans only through three uncontrolled case series.
Neither fact disposes of the other. The 2025 Inflammopharmacology commentary on Sikiric’s thirty-year body of work describes the peptide as a hormone-like gastro-protectant with apparently low toxicity in the doses tested, while flagging unresolved questions about structure-activity relationships and pharmacogenetics. The same reviews that catalogue the preclinical effects raise theoretical concerns: VEGFR2-mediated angiogenesis could be problematic in malignant or pre-malignant settings; proline metabolites can activate proline oxidase and generate reactive oxygen species; excessive nitric oxide production may impair drug metabolism[18]. None of this is resolved. None of it will be resolved without controlled human work.